{"id":389788,"date":"2022-08-24T00:00:00","date_gmt":"2022-08-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2022-biopharma-breast-cancer-current-treatment-physician-insights-us-2022\/"},"modified":"2026-05-04T11:30:27","modified_gmt":"2026-05-04T11:30:27","slug":"cutron0009-2022-biopharma-breast-cancer-current-treatment-physician-insights-us-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2022-biopharma-breast-cancer-current-treatment-physician-insights-us-2022\/","title":{"rendered":"Breast Cancer | Current Treatment: Physician Insights | US | 2022"},"content":{"rendered":"<p>Hormone receptor (HR)-positive \/ HER2-negative breast cancer has the highest incidence of all breast cancer subtypes. Treatment decisions are influenced by the stage of the disease, the patient\u2019s menopausal status, resectability, the site of metastasis, and treatment history. The FDA\u2019s approval of three CDK4\/6 inhibitors in the metastatic setting (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio) has changed physicians\u2019 prescribing behavior and created new dynamics in treatment sequencing. This drug class has proven particularly effective when combined with hormonal agents. Additional effective treatments are the PARP inhibitors (AstraZeneca \/ Merck &#038; Co.\u2019s Lynparza and Pfizer\u2019s Talzenna) for metastatic germline <em>BRCA<\/em>-mutation-positive HER2-negative (including HR-positive) breast cancer and the PI3K inhibitor (Novartis\u2019s Piqray) for advanced <em>PIK3CA<\/em>-mutation-positive HR-positive \/ HER2-negative disease.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How are HR-positive \/ HER2-negative patients mapped in terms of important patient characteristics, such as menopausal status, risk of recurrence, speed of disease progression, and metastatic site?<\/li>\n<li>According to surveyed physicians, what is the patient share of key drugs and combinations used to treat HR-positive \/ HER2-negative breast cancer, by line of therapy?<\/li>\n<li>What are the key drivers and obstacles determining current prescribing of CDK4\/6 inhibitors for HR-positive \/ HER2-negative metastatic breast cancer?<\/li>\n<li>Where do PARP and PI3K inhibitors fit into the treatment algorithm for HR-positive \/ HER2-negative disease?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em><strong>Current Treatment: Physician Insights<\/strong><\/em> provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered:<\/strong> United States.<\/p>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 100 medical oncologists in the United States fielded in June 2022.<\/p>\n<p><strong>Key drugs: <\/strong>Ibrance, Kisqali, Verzenio, Lynparza, Piqray, Talzenna, Afinitor, fulvestrant.<\/p>\n","protected":false},"template":"","class_list":["post-389788","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389788\/revisions"}],"predecessor-version":[{"id":576216,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389788\/revisions\/576216"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}